{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.6","upperLimit":"7.0","value":"4.5"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"3.8","value":"1.1"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"description":"Overall response rate is defined as the proportion of participants with confirmed CR or PR per the modified Response Evaluation Criteria in Solid Tumours (RECIST) for pleural mesothelioma or RECIST v1.1 for peritoneal mesothelioma and assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Complete Response (CR) corresponds to disappearance of all target lesions, and Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions. Overall Response (OR) = CR + PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tremelimumab 10mg/kg","id":"OG000","title":"TREMELIMUMAB"},{"description":"Placebo.","id":"OG001","title":"PLACEBO"}],"paramType":"NUMBER","populationDescription":"ITT population","reportingStatus":"POSTED","timeFrame":"Time from randomization to best response to treatment, assessed up to 3 years.","title":"Overall Response Rate by Treatment Arm","type":"SECONDARY","typeUnitsAnalyzed":"Participants","unitOfMeasure":"Percentage"}